8-K: Titan Pharmaceuticals Secures $1 Million Private Placement to Regain Nasdaq Compliance

Titan Pharmaceuticals completed a $1 million private placement of convertible preferred stock to address Nasdaq's minimum stockholders' equity requirement.

Summary

• Titan Pharmaceuticals was notified by Nasdaq that it did not meet the minimum $2.5 million stockholders' equity requirement for continued listing.
• To address this, Titan entered into a Securities Purchase Agreement with Blue Harbour Asset Management L.L.C-FZ.
• Titan issued 100,000 shares of Series B Convertible Preferred Stock to Blue Harbour at $10.00 per share, totaling $1,000,000.
• As of April 22, 2025, Titan believes it has met the minimum stockholders' equity requirement.
• Nasdaq will continue to monitor Titan's compliance, and the company may face delisting if it fails to meet the Equity Rule in future periodic financial statements.
• ARC Group Ltd. served as sole financial advisor to Titan in the private placement.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company faced a compliance issue, it successfully raised capital to address it. However, ongoing monitoring by Nasdaq introduces uncertainty.

Positives

• Titan Pharmaceuticals successfully raised $1 million through a private placement.
• The company believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement.
• The private placement included a beneficial ownership conversion blocker to limit Blue Harbour's ownership to 19.99% without shareholder approval.

Negatives

• Titan Pharmaceuticals was initially non-compliant with Nasdaq's minimum stockholders' equity requirement.
• The company is subject to ongoing monitoring by Nasdaq and could face delisting if it fails to maintain compliance.

Risks

• Titan Pharmaceuticals faces the risk of delisting from Nasdaq if it fails to maintain compliance with the Equity Rule.
• The company's ability to raise capital is a significant risk factor.
• Regulatory approval processes and the development, testing, production, and marketing of drug candidates pose risks.
• Patent and intellectual property matters could negatively impact the company.
• Strategic agreements and relationships are subject to risks and uncertainties.

Future Outlook

Nasdaq will continue to monitor the Company to ensure its ongoing compliance with the Equity Rule and, if at the time of filing of the Company's next periodic financial statements that covers the period following the closing of the Private Placement, the Company does not evidence compliance with the Equity Rule, the Company may be subject to delisting from Nasdaq.

Management Comments

• Titan Pharmaceuticals believes it has stockholders equity of at least $2.5 million as of the date of this filing.
• Titan Pharmaceuticals awaits Nasdaq's formal confirmation that it has evidenced compliance with the Equity Rule.

Industry Context

Small-cap pharmaceutical companies often face challenges in maintaining Nasdaq listing compliance due to fluctuating stock prices and capital needs; private placements are a common strategy to address these issues.

Comparison to Industry Standards

• Many small-cap biotech companies, such as ADMA Biologics and Biofrontera, have faced similar Nasdaq compliance issues related to minimum stockholders' equity.
• Private placements are a standard method for these companies to raise capital and regain compliance, similar to offerings by companies like Diffusion Pharmaceuticals.
• The $1 million raise is relatively small compared to some industry peers, but it is sufficient to address the immediate compliance issue.

Stakeholder Impact

• Shareholders: The private placement dilutes existing shareholders but addresses the risk of delisting.
• Employees: Continued Nasdaq listing provides stability for employees.
• Customers: No direct impact on customers.
• Suppliers: No direct impact on suppliers.
• Creditors: Improved financial position reduces credit risk.

Next Steps

• Titan Pharmaceuticals awaits formal confirmation from Nasdaq that it has evidenced compliance with the Equity Rule.
• Nasdaq will continue to monitor the Company to ensure its ongoing compliance with the Equity Rule.
• Titan Pharmaceuticals will file its next periodic financial statements.

Key Dates

Keywords

private placement, Nasdaq compliance, stockholders equity, convertible preferred stock, TTNP, Titan Pharmaceuticals, Blue Harbour, delisting